Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine

摘要: Antigen-presenting cells including dendritic (DCs) express mannan receptors (MR) on their surface, which can be exploited in cancer therapy by designing immune-stimulatory viruses coated with mannan-modified capsids that then bind to DCs and initiate a potent immune response. Although the combination of anti-angiogenesis immunotherapy agents has synergistic antitumor effect, more effective strategies for delivering such combinations are still required. Here we report design application adenovirus expresses both telomerase reverse transcriptase (TERT) vascular endothelial growth factor receptor-2 (VEGFR-2). Cytotoxic T lymphocytes reactive TERT VEGFR-2 capable mounting an anti-tumour response murine breast colon tumour models lung metastatic model. Compared vaccine or alone, combined showed remarkably immunity these models. Both TERT- VEGFR-2-specific cytotoxic (CTL) were identified vitro cytotoxicity assay, CTL activity against was significantly elevated group. Furthermore, CTL-mediated toxicity blocked anti-CD8 monoclonal antibodies. Thus, confers targeting intratumoural angiogenesis.